CN109771659A - A kind of weary oxygen responsive nano pharmaceutical carrier and its preparation method and application - Google Patents
A kind of weary oxygen responsive nano pharmaceutical carrier and its preparation method and application Download PDFInfo
- Publication number
- CN109771659A CN109771659A CN201910138839.4A CN201910138839A CN109771659A CN 109771659 A CN109771659 A CN 109771659A CN 201910138839 A CN201910138839 A CN 201910138839A CN 109771659 A CN109771659 A CN 109771659A
- Authority
- CN
- China
- Prior art keywords
- solution
- drug
- nitroimidazole
- nano
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention provides a kind of weary oxygen responsive nano drugs and its preparation method and application, and the Nano medication includes hydrophobicity seed kernel and amphiphilic shell.Wherein, the hydrophobicity seed kernel includes chlorin e 6 and Tirapazamine, the amphiphilic shell is the hydrophilic high mol hyaluronic acid of hydrophobic molecule 2- nitroimidazole modification, and hydrophobicity seed kernel and amphiphilic shell form unconjugated positional relationship with hydrophobe active force.The present invention passes through optimization preparation process, Nano medication is finally successfully prepared, particle size is moderate controllable, and laser irradiation of nano drug carries out optical dynamic therapy and consumes oxygen, and hydrophobic molecule 2- nitroimidazole is changed into hydrophilic molecules 2- aminooimidazole under hypoxic condition, Nano medication is dismissed, realize drug release, activated chemotherapy drug Tirapazamine chemotherapeutic toxicity, combination therapy are synergistic simultaneously for hypoxic condition, effectively killing cancer cell, has broad application prospects and huge market value.
Description
Technical field
The invention belongs to technical field of nano material, it is related to a kind of weary oxygen responsive nano pharmaceutical carrier and preparation method thereof
And application.
Background technique
Breast cancer disease incidence in global women is very high, especially the lethality of triple negative breast cancer (MDA-MB-231)
It is especially high, and currently without effective treatment means.Clinic generallys use methods of chemotherapy and carries out aftertreatment.But chemotherapy has
Whole body system toxicity is big, lesions position intake is low, is also easy to produce the defects of multidrug resistance.In the past few decades, nanometer medicine
Object, which has become, improves the very promising tool of conventional chemotherapeutic drugs therapeutic index.Nano medication size 1~100nm it
Between, due to solid tumor high-permeability and retention effect can drug-rich in the realization tumour of selectivity, while can also be big
It is big to reduce Nano medication general toxicity.
Currently, huge technical progress is had been achieved in this field, however, what limitation Nano medication was converted to clinic
One obstacle is derived to the controlled release for containing drug.The cis-platinum SPI-77 of liposome entrapment shows that specific ionization cis-platinum is bigger
Accumulation, however, drug bioavailability is poor when due to drug release, fails through III clinical trial phase in tumour.By additional
Stimulation is one of the effective ways for realizing drug specificity release using tumor microenvironment.
Compared with normal tissue, due to the imbalance between oxygen supply and consumption, anoxic is many malignant solid tumors
Common trait.Therefore, how to design a kind of respond using tumor hypoxia microenvironment and realize that the Nano medication of drug release reaches
Better oncotherapy effect is the research emphasis of this field
Summary of the invention
In view of the deficiencies of the prior art, the purpose of the present invention is to provide a kind of weary oxygen responsive nano pharmaceutical carrier and its
Preparation method and application.The present invention can realize the drug release of tumor microenvironment specificity after laser irradiation and chain control
It treats.
In order to achieve that object of the invention, the invention adopts the following technical scheme:
A kind of weary oxygen responsive nano drug, the Nano medication include hydrophobicity seed kernel and amphiphilic shell.Its
In, the hydrophobicity seed kernel includes chlorin e 6 and Tirapazamine, and the amphiphilic shell is hydrophobic molecule 2- nitro
The hydrophilic high mol hyaluronic acid (HA) of imidazoles (NI) modification.
In the present invention, the hyaluronic acid of the 2- nitroimidazole modification can visually be expressed as structure:
In the present invention, the HA that the Nano medication is modified with the 2- nitroimidazole of anoxic sensitivity is amphiphilic carrier, to dredge
Water drug chlorin e 6 and Tirapazamine are self-assembled into Nano medication by hydrophobe active force as therapeutic agent.By swashing
Light triggering chlorin e 6 carries out optical dynamic therapy and consumes oxygen, and the weary oxygen environment of construction not only makes hydrophobic molecule 2- on carrier
Nitroimidazole becomes hydrophilic molecules 2- aminooimidazole and Nano medication structure is promoted to dismiss, and promotes drug release, and further swash
The chemotherapeutic toxicity of drug Tirapazamine living, may be implemented the optical dynamic therapy of laser triggering and the chain therapy of chemotherapy.Make
Nano medication can be delivered to the position of triple negative breast cancer cell for the HA of the ligand of targets neoplastic cells in nanosystems,
To guarantee concentration effect in its tumor.
Preferably, the average grain diameter of the Nano medication be 40~50nm, such as: 40nm, 41nm, 43nm, 44nm,
45nm、46nm、47nm、49nm、50nm。
For nano-drug transporter of the present invention in spherical, particle diameter distribution is uniform.
Preferably, the carrying drug ratio of chlorin e 6 is 0.4~0.6% in the Nano medication, such as: 0.4%,
0.45%, 0.55%, 0.55%, 0.6%.
0.95% preferably, the carrying drug ratio of Tirapazamine is 0.9~1.1% in the Nano medication, such as: 0.9%,
1.0%, 1.05%, 1.1%.
Preferably, the grafting rate of 2- nitroimidazole modification hyaluronic acid is 7~8% in the Nano medication, such as: 7%,
7.1%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.9%, 8%.
Second technical solution of the invention is to provide a kind of preparation method of weary oxygen responsive nano drug as described above,
The preparation method is that: 2- nitroimidazole and hyaluronic acid react to obtain amphiphilic carrier material, then amphiphilic carrier
Material and dewatering medicament self assembly obtain nanoassemble body, the as described Nano medication.
In the present invention, 2- nitroimidazole modification hyaluronic acid preparation method the following steps are included:
(1) 2- nitroimidazole is dissolved in n,N-Dimethylformamide, adds potassium carbonate, in room temperature and magnetic agitation item
Under part, the N-Boc- bromine ethylamine solution for being dissolved in n,N-Dimethylformamide is added dropwise, is transferred to oil bath reaction.It is insoluble to filter removing
Object, and cleaned with methanol, by clear solution concentrated by rotary evaporation, obtain orange/yellow solid.The solid obtained again with ultrapure water dispersion, and
It is extracted with ethyl acetate, removes existing moisture with anhydrous sodium sulfate, suction filtration obtains anhydrous ethyl acetate solution, and revolving is glued
Thick liquid (NI-NH2- BOC), the methanol solution containing hydrochloric acid is added, magnetic agitation, to remove BOC group, revolving removes first
Alcohol obtains viscous product NI derivative.
(2) hyaluronic acid is dissolved in PBS, it is living that 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride is added
- the COOH for changing hyaluronic acid, adds-the COOH that n-hydroxysuccinimide stablizes activation, and it is molten that PBS is added under agitation
The NI derivative of solution, is stirred to react, and first dialyses in water alcohol dialyzate and is lyophilized after then dialysing in ultrapure water, obtains amphiphilic
Carrier HA-NI.
Preferably, the concentration of step (1) the 2- nitroimidazole solution is 0.12~0.15M, such as: 0.12M, 0.13M,
0.14M,0.15M；
Preferably, the molar ratio of step (1) the 2- nitroimidazole and N-Boc- bromine ethamine is 1:1~1:3, such as 1:1,
1:2,1:3；
Preferably, step (1) oil bath temperature is 70 DEG C~90 DEG C, such as 70 DEG C, 75 DEG C, 80 DEG C, 85 DEG C, 90 DEG C；
Preferably, step (1) the oil bath reaction time is 3~5 hours, such as 3 hours, 4 hours, 5 hours；
Preferably, step (1) the magnetic agitation time is 12~48 hours, such as 12 hours, 24 hours, 48 hours；
Preferably, the methanol solution of the step (1) containing hydrochloric acid is the methanol ice solution containing 1~1.5M hydrochloric acid, example
Such as 1.05M, 1.15M, 1.2M, 1.25M, 1.3M, 1.35M, 1.4M, 1.5M；
Preferably, step (2) hyaluronic acid and anakmetomeres 1- (3- dimethylamino-propyl) -3- ethyl carbodiimide
The molar ratio of hydrochloride and n-hydroxysuccinimide is 1:2:2~1:4:4, such as 1:2:2,1:3:3,1:4:4；
Preferably, the molar ratio of the hyaluronic acid Yu 2- nitroimidazole of the step (2) is 1:1.2~1:1.5, such as 1:
1.2,1:1.3,1:1.4,1:1.5；
Preferably, the temperature that is stirred to react of the step (2) is room temperature；
Preferably, the time that is stirred to react of the step (2) is 12~48 hours, for example, 12 hours, 24 hours, it is 48 small
When；
Preferably, step (2) dialysis is carried out using the bag filter that molecular cut off is 8000-14000；
Preferably, step (2) the water alcohol dialysis liquid proportional is water: methanol=1:1；
Preferably, the time of step (2) dialysis is 1~3 day (such as 1 day, 1.5 days, 2 days, 2.5 days, 3 days), often
4-6 hours (such as 4 hours, 4.5 hours, 5 hours, 5.5 hours or 6 hours) replacement dialyzates.
In the present invention, the Nano medication assemble method the following steps are included:
(1) chlorin e 6 and Tirapazamine are dissolved in organic solvent respectively, obtain drug solution；
(2) HA-NI is soluble in water, obtain carrier solution；
(3) two kinds of drug solutions for obtaining step (1) mix, and the carrier that step (2) obtain is added under ultrasound condition
In solution, lotion is formed；
(4) organic solvent is removed by revolving, removes uncoated drug with membrane filtration, obtains the nano-drug transporter
Aqueous systems.
Preferably, step (1) organic solvent be methylene chloride, trichlorine or dimethyl sulfoxide in any one or extremely
Few two kinds of combination；
Preferably, the concentration of step (1) drug solution is 0.1~0.5mg/mL, such as 0.1mg/mL, 0.2mg/
mL,0.3mg/mL,0.4mg/mL,0.5mg/mL；
Preferably, the concentration of step (2) carrier solution is 4~6mg/mL, such as 4mg/mL, 4.5mg/mL, 5mg/
mL,5.5mg/mL,6mg/mL；
Preferably, the volume ratio that the drug solution that step (1) obtains is mixed with the carrier solution that step (2) obtains is 1:4
~1:6, such as 1:4,1:5,1:6；
Preferably, step (3) chlorin e 6 and the mass ratio of two kinds of drugs of Tirapazamine mixing are 1:0.5~1:
2, such as 1:0.5,1:1,1:1.5,1:2；
Preferably, step (3) ultrasonic power is 10%~15%, such as 10%, 11%, 12%, 13%, 14%,
15%；
Preferably, step (3) ultrasonic time is 5min~10min, such as 5min, 6min, 7min, 8min, 9min,
10min；
Preferably, step (4) filter membrane is 220nm water system filter membrane.
Third technical solution of the invention is application of the Nano medication in treatment tumour；
Preferably, the tumour is source of people triple negative breast cancer MDA-MB-231.
In the treatment of triple negative breast cancer, pharmaceutical carrier hyaluronic acid has targeting left and right to its highly expressed CD44,
Nano medication can be helped more effectively to be enriched in tumor locus as targeted molecular, under specific laser irradiation, Ce6 can pass through
Optical dynamic therapy promotes apoptosis of tumor cells.Optical dynamic therapy can consume oxygen and build weary oxygen environment, release pharmaceutical carrier dismission
Radiotherapy and chemotherapy medicine, while Tirapazamine chemotherapeutic toxicity is activated, apoptosis of tumor cells is promoted by chemotherapy, Nano medication of the present invention is logical
A step laser irradiation induced drug is crossed to discharge and trigger interlock type treatment triple negative breast cancer.
Compared with the existing technology, the invention has the following advantages:
The present invention is used as carrier by HA-NI, using chlorin E6 and Tirapazamine as therapeutic agent, special laser irradiation
The chain process of drug release and optical dynamic therapy and chemotherapy may be implemented, the common killing improved for tumour cell
Effect.Using hyaluronic acid as carrier, enhancing Nano medication further promotes in drug tumor the targeting of triple negative breast cancer
Enrichment guarantees the effect of its treatment, has broad application prospects.
Detailed description of the invention
Fig. 1 is hyaluronic acid (HA-NI) preparation process of weary oxygen sensitive carrier 2- nitroimidazole modification provided by the invention
In nuclear magnetic spectrogram, wherein Figure 1A be carrier prepare needed for raw material 2- nitroimidazole (NI) nuclear magnetic spectrogram, Figure 1B be carrier system
The nuclear magnetic spectrogram of standby intermediate product 2- nitro imidazole derivatives, Fig. 1 C is the nuclear magnetic spectrogram for preparing products therefrom HA-NI；
Fig. 2 is NI provided by the invention, and NI derivative, HA-NI and the ultraviolet of Nano medication (Ce6/TPZ@HA-NI) can
See absorption spectrogram；
Fig. 3 is the result figure of chlorin e 6 light power performance in verifying Nano medication provided by the invention；
Fig. 4 is the result figure of the verifying weary oxygen sensitivity of nano-medicament carrier provided by the invention, and wherein Fig. 4 A is HA-NI weary
The curve that feature ultraviolet absorption peak changes at 330nm under the conditions of oxygen, Fig. 4 B are that feature is purple at 330nm under hypoxic condition by HA-NI
The linear fit of outer absorption peak variation；
Fig. 5 is the transmission electron microscope picture that the weary oxygen of Nano medication provided by the invention responds pattern variation；
Fig. 6 is the CCK-8 result figure that Nano medication provided by the invention influences MDA-MB-231 cell activity.
Specific embodiment
Further to illustrate technological means and its effect adopted by the present invention, below in conjunction with attached drawing and by specific real
Mode to further illustrate the technical scheme of the present invention is applied, but the present invention is not limited in scope of embodiments.
Embodiment 1
In the present embodiment, the Nano medication is that 2- nitroimidazole and hyaluronic acid react to obtain amphiphilic drug
Carrier, then amphiphilic pharmaceutical carrier and dewatering medicament self assembly obtain Nano medication.
It is prepared by the following method to obtain Nano medication, specifically includes the following steps:
(1) synthesis of amphiphilic pharmaceutical carrier
It weighs 149.6mg 2- nitroimidazole and is dissolved in 10mLN, in dinethylformamide, be added in Xiang Shangshu solution
The N-Boc- bromine ethamine for being dissolved in 1mL n,N-Dimethylformamide is added dropwise under the conditions of room temperature and magnetic agitation in 280mg potassium carbonate
Solution (200mg, 400mg or 600mg) is transferred to 70 DEG C, 80 DEG C or 90 DEG C oil baths, reacts 3h, 4h or 5h.It is insoluble to filter removing
Object, and cleaned with methanol, by clear solution concentrated by rotary evaporation, obtain orange/yellow solid.The solid obtained again with ultrapure water dispersion, and
It is extracted with ethyl acetate twice except by-product, removes existing moisture with anhydrous sodium sulfate, then filtered to obtain anhydrous second
Acetate solution.Revolving obtains viscous liquid (NI-NH2- BOC), the first that 10mL contains 1M, 1.25M or 1.5M hydrochloric acid is added
Alcohol ice solution, magnetic agitation 12h, for 24 hours or 48h is to remove BOC group.Revolving removes methanol, obtains viscous product NI derivative.
120mg, 180mg or 240mg hyaluronic acid are weighed in 100mL round-bottomed flask, the PBS of 10mL pH=7.4 is added
Dissolution takes 560mg 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride PBS dissolution to be added living in round-bottomed flask
Change-the COOH of hyaluronic acid, then takes 390mg n-hydroxysuccinimide PBS dissolution to be added in round-bottomed flask and stablize activation
- COOH, add the NI derivative of 160mg, 180mg or 200mg PBS dissolution under agitation, room temperature magnetic agitation is anti-
12h, for 24 hours or 48h is answered, first dialysis 1 day, 2 days or 3 days in water alcohol dialyzate (water: methanol=1:1), then in ultrapure water
Dialysis is lyophilized after 1 day, 2 days or 3 days, obtains amphiphilic carrier HA-NI.
(2) prepared by Nano medication self assembly
1mg chlorin e 6 is weighed respectively and Tirapazamine is dissolved in 2mL chloroform, and 5 μ L dimethyl sulfoxides are respectively added and help
It is molten to obtain drug solution, weigh 10mg HA-NI and be dissolved in 2mL water, obtain carrier solution, take 300 μ L, 400 μ L or 500 μ L by
Two kinds of drug solutions of 1:1 mixing are added dropwise in 2mL carrier solution under 10%, 12% or 15% ultrasonic power, 5 points of ultrasound
Clock, 7 minutes or 10 minutes formation lotions.Organic solvent is removed by revolving, removes uncoated medicine with the membrane filtration of 220nm
Object obtains the aqueous systems of the nano-drug transporter.
Embodiment 2
The intermediate product and final product being grafted on hyaluronic acid using nucleus magnetic hydrogen spectrum to 2- nitroimidazole are verified,
The result is shown in Figure 1.
Figure 1A is the nuclear magnetic spectrum of 2- nitroimidazole, and after reacting with N-Boc- bromine ethamine, the position b H is substituted, and obtains Figure 1B
The nuclear magnetic spectrogram of 2- nitro imidazole derivatives；The amino on-COOH and 2- nitro imidazole derivatives being activated on hyaluronic acid
Condensation reaction occurs, obtains HA-NI, from Fig. 1 C can be seen that HA-NI have with the H of Figure 1B 2- nitro imidazole derivatives it is similar
Chemical environment.
Embodiment 3
Successful grafting and two kind of the 2- nitroimidazole on hyaluronic acid are verified using ultraviolet-uisible spectrophotometer
Drug is wrapped up by amphiphilic carrier.
As a result as shown in Figure 2, in ultraviolet-visible absorption spectroscopy, HA-NI shows ultraviolet absorption peak of the NI at 330nm,
Further prove grafting of the NI on HA；The ultraviolet-visible absorption spectroscopy of NPs show simultaneously HA-NI at 330nm, Ce6 exists
As a result peak type of the 400nm and TPZ at 470nm demonstrates Ce6 and TPZ and is wrapped in HA-NI Nano medication simultaneously.
Embodiment 4
Using the light power performance of chlorin e 6 in singlet oxygen detection probe verifying Nano medication in the present embodiment.
The dimethyl sulphoxide solution for taking 2 μ L to contain 6 μ g/mL chlorin e 6s is uniformly dispersed in 2mL water, and it is dense that 40 μ L are added
The singlet oxygen detection probe that degree is 100 μM adds 4 oil drippings and carries out oil sealing to liquid level, uses 0.1W/cm2655nm laser shines
After penetrating solution different time, under sepectrophotofluorometer 488nm laser excitation, detection 500nm~650nm wavelength emits section
Interior fluorescence intensity.
Fig. 3 is the production and negative control that singlet oxygen detection probe detects singlet oxygen in Nano medication solution
Chlorin e 6 solution and positive control have chlorin e 6 solution under illumination condition to generate singlet oxygen under non-illuminated conditions
Situation.It can be seen from the figure that the singlet oxygen of generation is more as laser irradiation time extends in Nano medication solution, tool
There are stronger smooth power performance and optical dynamic therapy potentiality.
Embodiment 5
The weary oxygen sensitivity of pharmaceutical carrier HA-NI after light power is verified in the present embodiment.
It takes 2mL to contain the Nano medication solution of 6 μ g/mL, 30 μ L is added and pass on hydrionic reduced form nicotinamide adenine
Dinucleotides phosphoric acid, in 0.1W/cm2Before 655nm laser irradiation and 30 minutes after laser irradiation, 60 minutes, 90 minutes, 120
Minute, 180 minutes, 240 minutes, 240 minutes detect 2- nitroimidazole at 330nm by ultraviolet-uisible spectrophotometer respectively
UV absorption intensity.
As a result as shown in figure 4, being built as irradiation time extends photosensitizer chlorin e 6 by light power consumption oxygen
Weary oxygen environment, 2- nitroimidazole are converted into the 2- aminooimidazole at 330nm without characteristic absorption peak, make ultraviolet at 330nm
Characteristic absorption peak intensity gradually decreases, and illustrates that the nano-medicament carrier has good weary oxygen responsiveness, can be used as Nano medication
Weary oxygen sensitive carrier.
Embodiment 6
Further to verify the weary oxygen responsiveness of nano-medicament carrier after light power oxygen consumption, the nanometer that will be prepared in embodiment 1
Drug is diluted to 0.5mg/mL with PBS, takes the diluted Nano medication PBS solution of 2mL that 100 μ L are added and passes on hydrionic reduced form
Nicotinamide-adenine dinucleotide phosphate, in 0.1W/cm2Before 655nm laser irradiation and 15 minutes, 45 points after laser irradiation
Clock and 50 μ L are taken out within 90 minutes respectively morphology characterization is carried out by transmission electron microscope.Sample preparation methods are as follows: will take out
Nano medication with ultrapure water dilute 100 times, and ultrasound 2min carry out decentralized processing, take 7 μ L dilution after Nano medication it is water-soluble
Drop is online in TEM copper test, is stored at room temperature, after solvent volatilizees dry completely, by 2% phosphotungstic acid negative staining liquid 12000rpm from
It the heart 5 minutes, takes 7 μ L supernatants gently to drip in negative staining 1 minute on the copper mesh for be loaded with Nano medication, siphons away negative staining with filter paper side
Liquid, for biological transmissioning electric mirror test after drying.
As a result as shown in figure 5, Nano medication is in pattern uniform-spherical before laser irradiation, and their shapes after laser irradiation
Shape changes, and the boundary of Nano medication as the irradiation time increases is no longer clear, and pattern becomes irregularly, and size is not
Uniform, Nano medication form becomes blurred when irradiating 90 minutes, and carrier is dismissed completely, and no light group Nano medication
Pattern is almost unchanged.
Embodiment 6
In the present embodiment, the nano-drug transporter prepared to embodiment 1 detects cell on triple negative breast cancer cell
Toxicity, the method is as follows:
MDA-MB-231 cell is dispersed in the DMEM high glucose medium containing 10% fetal calf serum, with 70,000/mL cell
Density is seeded in 96 orifice plates, and it is 100 μ L that volume, which is added, in every hole.When cultivating 24 hour cells and reaching 80% fusion, by cell point
It is seven groups, cell culture medium is respectively adopted, the Nano medication for loading chlorin e 6, the Nano medication for loading Tirapazamine, bears
The Nano medication processing and three kinds of Nano medications for carrying chlorin e 6 and Tirapazamine use 655nm after handling two hours respectively
Laser is with 0.1W/cm2The every hole 7min of power illumination.After being incubated for for 24 hours again, 10 μ L CCK-8 are added in every hole, with enzyme mark after two hours
Instrument measures the absorbance at 450nm.With the absorbance for the cell being incubated for altogether with drug divided by the absorbance of blanc cell and with hundred
Ratio is divided to indicate as a result to see Fig. 6 to calculate cell viability.
As shown in fig. 6, chlorin e 6 and Tirapazamine all show weaker cytotoxicity compared with light group, tool
There is certain biological safety, compared with only optical dynamic therapy and only chemotherapy group, while having optical dynamic therapy and chemotherapy concurrently
Nano medication shows higher cytotoxicity to MDA-MB-231 cell, the results showed that the Nano medication can effectively inhibit three
The survival activity of negative breast cancer cells.
In conclusion Nano medication moderate in grain size provided by the invention is controllable, it is dynamic that laser irradiation of nano drug can trigger light
Power is treated and the chain treatment of chemotherapy, and weary oxygen caused by optical dynamic therapy can trigger carrier dismission drug release simultaneously and chemotherapy swashs
It is living, cancer cell is effectively killed, is had broad application prospects and huge market value
The Applicant declares that the present invention is explained by the above embodiments weary oxygen responsive nano pharmaceutical carrier of the invention and
Preparation method and application, but the method detailed during the present invention is not limited to the above embodiments, that is, do not mean that the present invention must
Above-described embodiment, which must be relied on, to be implemented.It should be clear to those skilled in the art, any improvement in the present invention, right
The equivalence replacement of each raw material of product of the present invention and addition, the selection of concrete mode of auxiliary element etc., all fall within guarantor of the invention
It protects within range and the open scope.
Claims (11)
1. a kind of weary oxygen responsive nano drug, which is characterized in that the Nano medication includes hydrophobicity seed kernel and parents
Property shell；
Wherein, the hydrophobicity seed kernel includes chlorin e 6 and Tirapazamine, and the amphiphilic shell is hydrophobic molecule
The hydrophilic high mol hyaluronic acid (HA) of 2- nitroimidazole (NI) modification,
The hyaluronic acid of 2- nitroimidazole modification is such as flowering structure:
2. weary oxygen responsive nano drug according to claim 1, which is characterized in that the average grain diameter of the Nano medication
For 40~50nm.
3. weary oxygen responsive nano drug according to claim 1, which is characterized in that chlorin in the Nano medication
The carrying drug ratio of e6 is 0.4~0.6%.
4. weary oxygen responsive nano drug according to claim 1, which is characterized in that Tirapazamine in the nanometer object
Carrying drug ratio be 0.9~1.1%.
5. weary oxygen responsive nano drug according to claim 1, which is characterized in that 2- nitro miaow in the nanometer object
The grafting rate that azoles modifies hyaluronic acid is 7~8%.
6. the preparation method of weary oxygen responsive nano drug according to any one of claims 1-5, which is characterized in that institute
Stating preparation method includes amount: 2- nitroimidazole and hyaluronic acid react to obtain amphiphilic carrier material 2- nitroimidazole modification
Hyaluronic acid, then amphiphilic carrier material and dewatering medicament self assembly obtain nanoassemble body, the as described nanometer medicine
Object.
7. the preparation method of weary oxygen responsive nano drug according to claim 6, which is characterized in that the 2- nitro miaow
Azoles modification hyaluronic acid preparation method the following steps are included:
(1) 2- nitroimidazole is dissolved in n,N-Dimethylformamide, adds potassium carbonate, in room temperature and magnetic agitation condition
Under, the N-Boc- bromine ethylamine solution for being dissolved in n,N-Dimethylformamide is added dropwise, is transferred to oil bath reaction；
It filters and removes insoluble matter, and cleaned with methanol, by clear solution concentrated by rotary evaporation, obtain orange/yellow solid；
The solid obtained again with ultrapure water dispersion, and be extracted with ethyl acetate, existing moisture is removed with anhydrous sodium sulfate, is filtered
Anhydrous ethyl acetate solution is obtained, revolving obtains viscous liquid (NI-NH2- BOC), the methanol solution containing hydrochloric acid, magnetic is added
Power stirring, to remove BOC group, revolving removes methanol, obtains viscous product NI derivative；
(2) hyaluronic acid is dissolved in PBS, it is saturating that the activation of 1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride is added
- the COOH of bright matter acid, adds-the COOH that n-hydroxysuccinimide stablizes activation, and PBS dissolution is added under agitation
NI derivative, is stirred to react, and first dialyses in water alcohol dialyzate and is lyophilized after then dialysing in ultrapure water, obtains amphiphilic carrier
HA-NI。
8. the preparation method of weary oxygen responsive nano drug according to claim 7, which is characterized in that the step (1)
The concentration of 2- nitroimidazole solution is 0.12~0.15M；
Preferably, the molar ratio of step (1) the 2- nitroimidazole and N-Boc- bromine ethamine is 1:1~1:3；
Preferably, step (1) oil bath temperature is 70~90 DEG C；
Preferably, step (1) the oil bath reaction time is 3~5 hours；
Preferably, step (1) the magnetic agitation time is 12~48 hours；
Preferably, the methanol solution of the step (1) containing hydrochloric acid is the methanol ice solution containing 1~1.5M hydrochloric acid；
Preferably, step (2) hyaluronic acid and anakmetomeres 1- (3- dimethylamino-propyl) -3- ethyl carbodiimide hydrochloride
The molar ratio of salt and n-hydroxysuccinimide is 1:2:2~1:4:4；
Preferably, the molar ratio of step (2) hyaluronic acid and 2- nitroimidazole is 1:1.2~1:1.5；
Preferably, it is room temperature that the step (2), which is stirred to react temperature,；
Preferably, the step (2) be stirred to react the time be 12~48 hours；
Preferably, step (2) dialysis is carried out using the bag filter that molecular cut off is 8000-14000；
Preferably, step (2) the water alcohol dialysis liquid proportional is water: methanol=1:1；
Preferably, the time of step (2) dialysis is 1~3 day, every 4~6 hours replacement dialyzates.
9. the preparation method of weary oxygen responsive nano drug according to claim 6, which is characterized in that the self assembly obtains
To nanoassemble body method the following steps are included:
(1) chlorin e 6 and Tirapazamine are dissolved in organic solvent respectively, obtain drug solution；
(2) HA-NI is soluble in water, obtain carrier solution；
(3) two kinds of drug solutions for obtaining step (1) mix, and the carrier solution that step (2) obtain is added under ultrasound condition
In, form lotion；
(4) organic solvent is removed by revolving, removes uncoated drug with membrane filtration, obtains the water of the nano-drug transporter
System.
10. the preparation method of weary oxygen responsive nano drug according to claim 9, which is characterized in that the step (1)
Organic solvent is the combination of any one or at least two in methylene chloride, trichlorine or dimethyl sulfoxide；
Preferably, the concentration of step (1) drug solution is 0.1~0.5mg/mL；
Preferably, the concentration of step (2) carrier solution is 4~6mg/mL；
Preferably, the volume ratio that the drug solution that the step (1) obtains is mixed with the carrier solution that step (2) obtains is 1:4
~1:6；
Preferably, step (3) chlorin e 6 and the mass ratio of two kinds of drugs of Tirapazamine mixing are 1:0.5~1:2；
Preferably, step (3) ultrasonic power is 10%~15%；
Preferably, step (3) ultrasonic time is 5min~10min；
Preferably, step (4) filter membrane is 220nm water system filter membrane.
11. application of the weary oxygen responsive nano drug according to any one of claims 1-5 in treatment tumour, preferably
Ground, the tumour are source of people triple negative breast cancer MDA-MB-231.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910138839.4A CN109771659A (en) | 2019-02-25 | 2019-02-25 | A kind of weary oxygen responsive nano pharmaceutical carrier and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910138839.4A CN109771659A (en) | 2019-02-25 | 2019-02-25 | A kind of weary oxygen responsive nano pharmaceutical carrier and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109771659A true CN109771659A (en) | 2019-05-21 |
Family
ID=66486934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910138839.4A Pending CN109771659A (en) | 2019-02-25 | 2019-02-25 | A kind of weary oxygen responsive nano pharmaceutical carrier and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109771659A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110452314A (en) * | 2019-08-07 | 2019-11-15 | 浙江大学 | Anoxic sensitivity response type chitosan nitroimidazole grafting and preparation and application |
| CN110841065A (en) * | 2019-12-05 | 2020-02-28 | 福州大学 | Nano compound for pH/hypoxia dual-response drug release synergistic photodynamic therapy and preparation method thereof |
| CN111135299A (en) * | 2020-02-26 | 2020-05-12 | 沈阳药科大学 | Construction of photosensitizer-hypoxia activated prodrug integrated prodrug self-assembled nanoparticles |
| CN111135309A (en) * | 2020-01-15 | 2020-05-12 | 重庆大学 | Tilazamine drug carrier with core-shell structure and preparation method and application thereof |
| CN111607078A (en) * | 2020-06-17 | 2020-09-01 | 苏州大学 | Hypoxic responsive cationic polymer and preparation method and application thereof |
| CN111840579A (en) * | 2020-08-05 | 2020-10-30 | 国家纳米科学中心 | Hypoxic imaging agent and preparation method and application thereof |
| CN112263566A (en) * | 2020-09-24 | 2021-01-26 | 中国药科大学 | Albumin-binding type anoxic-oxidation dual-responsiveness composite nanoparticle, preparation method and application |
| CN112516329A (en) * | 2020-12-28 | 2021-03-19 | 中国药科大学 | Self-assembled combined drug carrier based on high-molecular prodrug and application thereof |
| CN113817164A (en) * | 2020-06-12 | 2021-12-21 | 北京化工大学 | Hypoxic sensitive drug carrier polymer and preparation method and application thereof |
| CN115531345A (en) * | 2021-06-30 | 2022-12-30 | 复旦大学 | Hypoxic response bionic nano delivery system and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309366A (en) * | 2016-09-19 | 2017-01-11 | 天津大学 | Preparation method of polystyrene-polyacrylic acid nanometer drug carrying microsphere for photodynamics therapy |
| CN107530296A (en) * | 2015-04-21 | 2018-01-02 | 北卡罗来纳州立大学 | Use the glucose responding insulin delivery system of hypoxia sensitivity nano composite material |
-
2019
- 2019-02-25 CN CN201910138839.4A patent/CN109771659A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107530296A (en) * | 2015-04-21 | 2018-01-02 | 北卡罗来纳州立大学 | Use the glucose responding insulin delivery system of hypoxia sensitivity nano composite material |
| CN106309366A (en) * | 2016-09-19 | 2017-01-11 | 天津大学 | Preparation method of polystyrene-polyacrylic acid nanometer drug carrying microsphere for photodynamics therapy |
Non-Patent Citations (3)
| Title |
|---|
| KAI ZHANG等: "Light-triggered theranostic liposomes for tumor diagnosis and combined photodynamic and hypoxia-activated prodrug therapy", 《BIOMATERIALS》 * |
| S.-JA TSENG等: "argeting Tumor Microenvironment by Bioreduction-Activated Nanoparticles for Light-Triggered Virotherapy", 《ACS NANO》 * |
| 何华: "光动力调控的纳米药物用于抗肿瘤治疗的研究", 《万方学位论文》 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110452314A (en) * | 2019-08-07 | 2019-11-15 | 浙江大学 | Anoxic sensitivity response type chitosan nitroimidazole grafting and preparation and application |
| CN110841065A (en) * | 2019-12-05 | 2020-02-28 | 福州大学 | Nano compound for pH/hypoxia dual-response drug release synergistic photodynamic therapy and preparation method thereof |
| CN111135309A (en) * | 2020-01-15 | 2020-05-12 | 重庆大学 | Tilazamine drug carrier with core-shell structure and preparation method and application thereof |
| CN111135309B (en) * | 2020-01-15 | 2023-04-28 | 重庆大学 | Tilazamine drug carrier with core-shell structure and preparation method and application thereof |
| CN111135299A (en) * | 2020-02-26 | 2020-05-12 | 沈阳药科大学 | Construction of photosensitizer-hypoxia activated prodrug integrated prodrug self-assembled nanoparticles |
| CN113817164A (en) * | 2020-06-12 | 2021-12-21 | 北京化工大学 | Hypoxic sensitive drug carrier polymer and preparation method and application thereof |
| CN111607078B (en) * | 2020-06-17 | 2022-06-03 | 苏州大学 | Hypoxic responsive cationic polymer and preparation method and application thereof |
| CN111607078A (en) * | 2020-06-17 | 2020-09-01 | 苏州大学 | Hypoxic responsive cationic polymer and preparation method and application thereof |
| CN111840579A (en) * | 2020-08-05 | 2020-10-30 | 国家纳米科学中心 | Hypoxic imaging agent and preparation method and application thereof |
| CN112263566A (en) * | 2020-09-24 | 2021-01-26 | 中国药科大学 | Albumin-binding type anoxic-oxidation dual-responsiveness composite nanoparticle, preparation method and application |
| CN112263566B (en) * | 2020-09-24 | 2022-06-24 | 中国药科大学 | Albumin-binding type anoxic-oxidation dual-responsiveness composite nanoparticle, preparation method and application |
| CN112516329A (en) * | 2020-12-28 | 2021-03-19 | 中国药科大学 | Self-assembled combined drug carrier based on high-molecular prodrug and application thereof |
| CN112516329B (en) * | 2020-12-28 | 2024-02-20 | 南京宁丹新药技术有限公司 | Self-assembled combined drug carrier based on macromolecule prodrug and application thereof |
| CN115531345A (en) * | 2021-06-30 | 2022-12-30 | 复旦大学 | Hypoxic response bionic nano delivery system and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109771659A (en) | A kind of weary oxygen responsive nano pharmaceutical carrier and its preparation method and application | |
| Pan et al. | Microenvironment-driven sequential ferroptosis, photodynamic therapy, and chemotherapy for targeted breast cancer therapy by a cancer-cell-membrane-coated nanoscale metal-organic framework | |
| Li et al. | Near-infrared light-initiated molecular superoxide radical generator: rejuvenating photodynamic therapy against hypoxic tumors | |
| Yu et al. | Oxygen self-sufficient NIR-activatable liposomes for tumor hypoxia regulation and photodynamic therapy | |
| Hou et al. | Tumor microenvironment responsive biomimetic copper peroxide nanoreactors for drug delivery and enhanced chemodynamic therapy | |
| Cheng et al. | Nanotherapeutics interfere with cellular redox homeostasis for highly improved photodynamic therapy | |
| Song et al. | Donor-acceptor structured photothermal COFs for enhanced starvation therapy | |
| Lu et al. | Biomimetic smart mesoporous carbon nanozyme as a dual-GSH depletion agent and O2 generator for enhanced photodynamic therapy | |
| Zeng et al. | Ultra-thin metal–organic framework nanosheets for chemo-photodynamic synergistic therapy | |
| Xia et al. | Glutathione responsive nitric oxide release for enhanced photodynamic therapy by a porphyrinic MOF nanosystem | |
| Zhang et al. | Glucose oxidase and polydopamine functionalized iron oxide nanoparticles: Combination of the photothermal effect and reactive oxygen species generation for dual-modality selective cancer therapy | |
| Zhang et al. | Folate and heptamethine cyanine modified chitosan-based nanotheranostics for tumor targeted near-infrared fluorescence imaging and photodynamic therapy | |
| Yao et al. | Tumor-targeted upconverting nanoplatform constructed by host-guest interaction for near-infrared-light-actuated synergistic photodynamic-/chemotherapy | |
| Yan et al. | A fullerene based hybrid nanoparticle facilitates enhanced photodynamic therapy via changing light source and oxygen consumption | |
| CN113559064B (en) | Novel self-oxygen-supply liposome nanoparticle and preparation method and application thereof | |
| Zhang et al. | An intelligent hypoxia-relieving chitosan-based nanoplatform for enhanced targeted chemo-sonodynamic combination therapy on lung cancer | |
| Zhang et al. | Research progress in the synthesis and biological application of quantum dots | |
| Duo et al. | AIEgen-based bionic nanozymes for the interventional photodynamic therapy-based treatment of orthotopic Colon cancer | |
| Zhu et al. | Sonodynamic cancer therapy by novel iridium-gold nanoassemblies | |
| Li et al. | A self-assembled nanoplatform based on Ag2S quantum dots and tellurium nanorods for combined chemo-photothermal therapy guided by H2O2-activated near-infrared-II fluorescence imaging | |
| CN111407743A (en) | Dopamine assembly drug delivery system and preparation method thereof | |
| Li et al. | Innovative design strategies advance biomedical applications of phthalocyanines | |
| Zhang et al. | A copper nanocluster-based multifunctional nanoplatform for augmented chemo/chemodynamic/photodynamic combination therapy of breast cancer | |
| Zhu et al. | A MnO2-coated multivariate porphyrinic metal–organic framework for oxygen self-sufficient chemo-photodynamic synergistic therapy | |
| Zhang et al. | A self-supplied O2 versatile nanoplatform for GOx-mediated synergistic starvation and hypothermal photothermal therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190521 |